Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease

Table 3 Drugs and vaccines used in the management and prevention of coronavirus disease 19

Classification		Drugs
Antiviral agents		Favipiravir, molnupiravir, paxlovid, remdesivir
Immunomodulatory agents
	JAK inhibitors	Baricitinib, ruxolitinib, tofacitinib
	Monoclonal antibodies to IL-6	Sarilumab, tocilizumab
	Corticosteroids	Cortisol, dexamethasone, methylprednisolone
	Monoclonal antibodies to SARS-CoV-2	Bamlanivimab, casirivimab, etesevimab, imdevimab, sotrovimab
COVID-19 vaccines
	mRNA	BNT162b2 [Pfizer-BioNTech], mRNA-1273 [Moderna]
	Adenovirus vector	ChAdOx1-S [AstraZeneca, Oxford]; Ad26.COV2.S [Johnson and Johnson, Janssen], Sputnik-V-Gam - COVID Vac Ad5+Ad26 [Gamleaya]
	Recombinant nanoparticles	NVX-CoV2373 [Novavax]
Miscellaneous agents		Azithromycin, chloroquine, dexamethasone, fluvoxamine, hydroxychloroquine, ivermectin

COVID-19: Coronavirus disease 19; IL-6: Interleukin-6; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.